Actively Recruiting
Platelet Aggregation in the Diagnosis of Acute Graft Rejection
Led by University Hospital, Martin · Updated on 2025-12-10
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating whether changes in platelet function can serve as non-invasive markers for detecting acute rejection in kidney transplant patients. This pilot observational study focuses on adult kidney transplant recipients, examining platelet aggregation and activation markers to understand their role in early kidney graft injury and immune response. The goal is to support diagnosis of acute cellular or antibody-mediated rejection alongside traditional biopsy methods. The study measures platelet function using optical aggregometry, flow cytometry for P-selectin expression, and soluble P-selectin levels. Two groups are observed: patients undergoing routine protocol biopsies at 3 and 12 months post-transplant, and patients with signs of graft dysfunction who receive indication biopsies. Alongside platelet assessments, the study collects biochemical, immunological, and donor-specific antibody data to correlate with biopsy results. Participants undergo platelet testing before transplant and at scheduled biopsy times or when graft dysfunction is suspected. Researchers review platelet activation profiles, histopathology, and clinical outcomes to assess their potential as non-invasive diagnostic tools. The study involves longitudinal monitoring of renal function, immunosuppression levels, and metabolic parameters to provide a comprehensive understanding of graft health over time.
CONDITIONS
Brief Title
Platelet Aggregation in the Diagnosis of Acute Graft Rejection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Primary kidney transplantation recipients
- Recipients of living or deceased donor kidneys
- Ability and willingness to provide informed consent
You will not qualify if you...
- Patients under 18 years of age
- Secondary or tertiary kidney transplantation recipients
- Patients currently on antiplatelet therapy
- Patients unable to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 months post-transplant and beyond as needed
Participants who have received a kidney transplant are monitored through protocol biopsies and clinical assessments to evaluate platelet aggregation and activation markers at scheduled time points and during suspected graft dysfunction.
Visits at pre-transplant baseline, 3 months, 12 months post-transplant, and at any time of indication biopsy due to graft dysfunction
Trial Site Locations
Total: 1 location
1
Transplant-Nephrology Department, University Hospital Martin
Martin, Slovakia, 03601
Actively Recruiting
Research Team
T
Timea Blichova, MD
P
Patricia Kleinova, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here